PTSD and Panic Attack Treatment Guidelines

Guideline-Recommended Pharmacotherapy

PTSD treatment guidelines do not include pregabalin as a recommended medication 1, 2, 3
For PTSD-associated symptoms, prazosin is the only medication with Level A recommendation for nightmares specifically 3
SSRIs (sertraline and paroxetine) are the FDA-approved and guideline-recommended medications for PTSD, with 53-85% of patients classified as treatment responders 2
Paroxetine 10-40mg/day or sertraline are the appropriate SSRI choices for PTSD and panic symptoms, with FDA approval and strong guideline support 2
SSRIs should be continued for at least 9-12 months after symptom remission to prevent relapse 1
SSRIs have demonstrated 53-85% response rates in PTSD across multiple well-controlled trials 2
26-52% of patients relapse when SSRI medication is stopped, compared to lower relapse rates after completing CBT 2

For panic attacks, CBT-based psychological treatment is the guideline-recommended approach 1
Trauma-focused cognitive behavioral therapy (CBT) should be offered immediately without requiring a stabilization phase, even in complex presentations 4, 5, 6
Specific CBT techniques include exposure therapy, cognitive restructuring, and stress inoculation training, with 42-65% of patients losing PTSD diagnosis after treatment 2
Delaying trauma-focused treatment can be demoralizing and iatrogenic, potentially reducing self-confidence and treatment motivation 4, 5
Avoid the misconception that "complex" presentations require stabilization before trauma-focused therapy - this is not supported by evidence and delays effective treatment 4, 5, 6

The American Academy of Family Physicians recommends paroxetine doses between 10-40mg/day for anxiety and depressive disorders, with the current 30mg dose being appropriate 7
Paroxetine has fewer cardiovascular concerns compared to tricyclic antidepressants, but regular monitoring for potential cardiac effects is recommended 7
The medication has more anticholinergic effects than other SSRIs but is generally well-tolerated 7, 8

Monitor for potential drug interactions as paroxetine can affect CYP2D6 metabolism 9
Consider adding cognitive-behavioral therapy (CBT), particularly exposure and response prevention techniques, which are first-line treatments for anxiety disorders and PTSD 10
Treatment should continue for at least 9-12 months after symptom remission to prevent relapse of depressive symptoms 11
If symptoms persist, consider optimizing paroxetine dose (up to 40mg if tolerated) 7
Augmentation strategies may be considered if partial response is achieved 10

Abrupt discontinuation of paroxetine should be avoided due to risk of discontinuation syndrome; if medication changes are needed, gradual tapering is essential 9
Regular reassessment of symptoms using validated scales is recommended to track treatment progress 8

The American Academy of Sleep Medicine recommends prazosin (not doxazosin) for PTSD-associated nightmares, with a Level A recommendation, typically dosed 1-10+ mg at bedtime with monitoring for orthostatic hypotension 12
The American Psychological Association guidelines support the use of trauma-focused psychotherapy and FDA-approved SSRIs (sertraline or paroxetine) as first-line treatments, with 53-85% response rates in controlled trials 13, 14

The American Academy of Sleep Medicine guidelines recommend adding prazosin (not doxazosin) to first-line treatment if nightmares persist, starting at 1mg at bedtime and titrating to effective dose (typically 3-10mg), with monitoring for orthostatic hypotension 12

The American Heart Association notes that doxazosin causes weight gain and increased heart failure risk, making it less desirable than other antihypertensives 15
The American Psychological Association emphasizes that trauma-focused therapy is safe even with comorbid substance abuse, borderline personality disorder, severe mental illness, or suicidal ideation 13, 14

The American Academy of Child and Adolescent Psychiatry recommends sertraline as a first-line treatment for PTSD and panic disorder, due to its favorable discontinuation profile compared to paroxetine, with a lower risk of discontinuation syndrome 16
Paroxetine is an effective alternative for PTSD, panic disorder, and multiple anxiety disorders, but has higher rates of discontinuation syndrome and more anticholinergic effects than other SSRIs, requiring careful tapering if discontinuation becomes necessary 17
The American Academy of Child and Adolescent Psychiatry suggests that paroxetine has higher rates of discontinuation syndrome and more anticholinergic effects than other SSRIs, and is associated with increased risk of suicidal thinking compared to other SSRIs, requiring closer monitoring in young adults 16

The American Academy of Child and Adolescent Psychiatry recommends initiating trauma-focused psychotherapy (Prolonged Exposure, Cognitive Processing Therapy, or EMDR) immediately alongside medication, not delayed for stabilization, with combined treatment showing superior outcomes compared to medication alone, with 40-87% of patients no longer meeting PTSD criteria after 9-15 sessions 16

The American Academy of Child and Adolescent Psychiatry suggests assessing treatment response at 4-6 weeks using standardized symptom rating scales for both PTSD and panic symptoms, and monitoring for treatment-emergent suicidality, particularly in the first 4-8 weeks, as black box warnings apply to young adults under age 25 16
The Mayo Clinic recommends monitoring for treatment-emergent suicidality, particularly in the first 4-8 weeks, as black box warnings apply to young adults under age 25 17